Diego Aizenberg

Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial

W. Timothy Garvey, Juan P. Frías, Ania M. Jastreboff et al. · The Lancet · 2023 · 590 citations · Full text

Obesity, Metabolic Syndrome, Diabetes Management +6

Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial

Stefano Del Prato, Steven E. Kahn, Imre Pávó et al. · The Lancet · 2021 · 586 citations

Metabolic Syndrome, Diabetes Management, Cardiovascular Disease +9

Effect of SGLT2 Inhibitors on Stroke and Atrial Fibrillation in Diabetic Kidney Disease

Zien Zhou, Meg Jardine, Qiang Li et al. · Stroke · 2021 · 111 citations · Full text

Efficacy and safety of sacubitril/valsartan in patients with essential hypertension uncontrolled by olmesartan: A randomized, double‐blind, 8‐week study

Deanna G. Cheung, Diego Aizenberg, Kudsia Hafeez et al. · Journal of Clinical Hypertension · 2018 · 69 citations · Full text

Blood Pressure Monitoring, Hypertension, Blood Pressure +13

Effect of Dapagliflozin in DAPA-HF According to Background Glucose-Lowering Therapy

Kieran F. Docherty, Pardeep S. Jhund, Olof Bengtsson et al. · Diabetes Care · 2020 · 42 citations · Full text